FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Fund ProfileVanEck Pharmaceutical ETF
  • Fund Overview
  • Fund Data
  • Peer Comparison
  • Ownership & News
PPH
VanEck Pharmaceutical ETF ETF AnalysisComprehensive ETF analysis for VanEck Pharmaceutical ETF (PPH) including NAV, expense ratio, dividend yield, sector breakdown, and holdings data.ETF AnalysisPPH
PPH
VanEck Pharmaceutical ETF
  • Fund Overview
  • Fund Data
  • Peer Comparison
  • Ownership & News
PPH
  1. Home
  2. Screener
  3. VanEck Pharmaceutical ETFPPHETF
VanEck Pharmaceutical ETF Logo

VanEck Pharmaceutical ETF

ETF
🇺🇸PPH•NASDAQ•Equity

Your view on PPH

VanEck Pharmaceutical ETF Logo

VanEck Pharmaceutical ETF

ETFVanEck
🇺🇸PPH•NASDAQ•Equity
AUM (USD)$1.09B
Expense Ratio0.36%
Yield (TTM)1.82%
Holdings26

Sentiment

—

AUM (USD)

$1.09B

Expense Ratio

0.36%

Yield (TTM)

1.82%

Holdings

26

Sentiment

—
Fund Overview

Overview

What the fund invests in, who runs it, and what it costs.

VanEck Pharmaceutical ETF (PPH) is an Equity fund from VanEck, listed since 2011, with $1.1B in assets under management, a 0.36% expense ratio and a NAV of $121.58 USD.

Overview for VanEck Pharmaceutical ETF

Fund Type
ETF
Fund Issuer
VanEck
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
December 20, 2011
Domicile
US
Website
vaneck.com/us/en/investments/pharmaceutical-etf-pph
Fund Type
ETF
Fund Issuer
VanEck
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
December 20, 2011
Domicile
US
Website
vaneck.com/us/en/investments/pharmaceutical-etf-pph
Fund Type
ETF
Fund Issuer
VanEck
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
December 20, 2011
Domicile
US
Website
vaneck.com/us/en/investments/pharmaceutical-etf-pph

About this fund

VanEck Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceutical…

Fund Data

Price Chart

Market price history and trading volume.

Key Facts

Cost, yield, size, and the fund's reference data.

Equity

Expense Ratio

0.36%

Yield (TTM)

1.82%

AUM

$1.09B

Fund Details

NAV$121.58 USD
Holdings26
Average Volume302.9K
Inception DateDecember 20, 2011
Asset ClassEquity
Fund IssuerVanEck
DomicileUS
ISINUS92189F6925
CUSIP92189F692
NAV CurrencyUSD

Expense Ratio

0.36%

Dividend Yield (TTM)

1.82%

Assets Under Management

$1.09B

NAV

$121.58 USD

Holdings

26

Average Volume

302.9K

Inception Date

December 20, 2011

Asset Class

Equity

Fund Issuer

VanEck

Domicile

US

ISIN

US92189F6925

CUSIP

92189F692

NAV Currency

USD

Expense Ratio

0.36%

Dividend Yield (TTM)

1.82%

Assets Under Management

$1.09B

NAV

$121.58 USD

Holdings

26

Average Volume

302.9K

Inception Date

December 20, 2011

Asset Class

Equity

Fund Issuer

VanEck

Domicile

US

ISIN

US92189F6925

CUSIP

92189F692

NAV Currency

USD

Distributions · last 12 months

Quarterly · 4 payments

Ex-datePaidAmount
Oct 1, 2026Oct 6, 2026$0.36
Jul 1, 2026Jul 7, 2026$0.6248
Apr 1, 2026Apr 7, 2026$0.8441
Dec 29, 2025Dec 31, 2025$0.3106
Total, 12 months$2.14 a share

Dividend yield (TTM) 1.82% = $2.14 paid per share in the 12 months to Nov 20, 2026 ÷ the $117.87 price. Past distributions; future payments can differ.

Data last updated: Nov 11, 2026, 08:10 AM

Sectors

How the fund's assets are split across sectors.

1 sectors
  • 1Healthcare
    100.0%

Top sector

Healthcare

Top weight

100.0%

Top 3 weight

100.0%

Holdings

The securities the fund owns, by weight.

27 positions
1LLYEli Lilly & Co
22.95%
2MRKMerck & Co Inc
11.72%
3NVONovo Nordisk A/S
5.40%
4MCKMckesson Corp
5.10%
5PFEPfizer Inc
4.71%
6TEVATeva Pharmaceutical Industries Ltd
4.70%
7CORCencora Inc
4.52%
8BMYBristol-Myers Squibb Co
4.31%
9GSKGsk Plc
4.19%
10ABBVAbbvie Inc
3.68%
11AZNAstrazeneca Plc
3.68%
12NVSNovartis Ag
3.64%
13SNYSanofi Sa/France
3.55%
14HLNHaleon Plc
3.45%
15JNJJohnson & Johnson
3.30%

Concentration

Total Holdings27
Top 10 Weight71.29%
Top HoldingLLY
Top Weight22.95%
1LLYEli Lilly & Co
22.95%
2MRKMerck & Co Inc
11.72%
3NVONovo Nordisk A/S
5.40%
4MCKMckesson Corp
5.10%
5PFEPfizer Inc
4.71%
6TEVATeva Pharmaceutical Industries Ltd
4.70%
7CORCencora Inc
4.52%
8BMYBristol-Myers Squibb Co
4.31%
9GSKGsk Plc
4.19%
10ABBVAbbvie Inc
3.68%
11AZNAstrazeneca Plc
3.68%
12NVSNovartis Ag
3.64%
13SNYSanofi Sa/France
3.55%
14HLNHaleon Plc
3.45%
15JNJJohnson & Johnson
3.30%

Total Holdings

27

Top 10 Weight

71.29%

Top Holding

LLY

Top Weight

22.95%

1LLYEli Lilly & Co
22.95%$240.42M
2MRKMerck & Co Inc
11.72%$122.78M
3NVONovo Nordisk A/S
5.40%$56.63M
4MCKMckesson Corp
5.10%$53.49M
5PFEPfizer Inc
4.71%$49.36M
6TEVATeva Pharmaceutical Industries Ltd
4.70%$49.27M
7CORCencora Inc
4.52%$47.38M
8BMYBristol-Myers Squibb Co
4.31%$45.19M
9GSKGsk Plc
4.19%$43.93M
10ABBVAbbvie Inc
3.68%$38.54M
11AZNAstrazeneca Plc
3.68%$38.52M
12NVSNovartis Ag
3.64%$38.18M
13SNYSanofi Sa/France
3.55%$37.18M
14HLNHaleon Plc
3.45%$36.20M
15JNJJohnson & Johnson
3.30%$34.53M

Total Holdings

27

Top 10 Weight

71.29%

Top Holding

LLY

Top Weight

22.95%

Peer Comparison

Comparables

Funds similar to this one.

Side by side on what an ETF is compared on11 funds
FundAsset classExpense ratioAssetsHoldings
PPHVanEck Pharmaceutical ETFThis fundEquity0.36%$1.1B26

Comparable funds

  • BBHVanEck Biotech ETFEquity0.35%$536M25
  • BKMCBNY Mellon US Mid Cap Core Equity ETFEquity0.04%$657M403
  • CXSEWisdomTree China ex-State-Owned Enterprises FundEmerging Markets Equity0.32%$380M205
  • EBILongview Advantage ETFEquity0.34%$685M0
  • FYCFirst Trust Small Cap Growth AlphaDEX FundSmall/Micro Cap Equity0.70%$1.4B264
  • IHEiShares US Pharmaceuticals ETFEquity0.37%$1.7B52
  • NUKZRange Nuclear Renaissance Index ETFEquity0.85%$591M52
  • OSEAHarbor International Compounders ETF (OSEA)Equity0.55%$374M30

More VanEck ETFs

  • WARPVanEck Space ETFEquity0.50%$37M21
  • XMPTVanEck CEF Muni Income ETFMulti-Asset3.40%$210M39
  • VSOLVanEck Solana ETFAlternatives0.30%$16M1
Ownership & News

Fund Holders

Institutions that own shares of this fund.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for this company. Press releases and market coverage, newest first.

News

Latest Market News

News

Latest Market News